SYGNAL DBM

K073329 · Musculoskeletal Transplant Foundation · MBP · Feb 28, 2008 · Orthopedic

Device Facts

• Record ID: K073329
• Device Name: SYGNAL DBM
• Applicant: Musculoskeletal Transplant Foundation
• Product Code: MBP · Orthopedic
• Decision Date: Feb 28, 2008
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3045
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Sygnal DBM is a bone void filler for voids or gaps that are not intrinsic to the stability of the bony structure. Sygnal DBM can be used to fill bone voids in the extremities and pelvis. It is indicated for use in the treatment of surgically-created osseous defects or osseous defects created from traumatic injury. Sygnal DBM is for single patient use only.

Device Story

Sygnal DBM is a resorbable bone void filler composed of donated cortical bone granules mixed with sodium hyaluronate and carboxymethylcellulose. Used by surgeons in clinical settings to fill non-structural osseous defects in extremities and pelvis resulting from surgery or trauma. Device acts as an osteoconductive scaffold to support bone healing. Every lot is assayed in an athymic mouse model to confirm osteoinductive potential prior to release. Product is single-patient use, aseptically processed, and sterilized.

Clinical Evidence

No clinical data provided. Evidence consists of biocompatibility testing per ISO 10993, sterility testing per USP <71>, and in vivo osteoinductive potential assessment using an athymic mouse model. Viral inactivation potential was evaluated using a panel of model human viruses.

Technological Characteristics

Composition: Donated cortical bone, sodium hyaluronate, carboxymethylcellulose. Form factor: Granules in 0.5 cc to 10.0 cc volumes. Principle: Osteoconductive bone void filler. Biocompatibility: ISO 10993. Sterilization: Aseptic processing, USP <71> compliant. Connectivity: None. Energy source: None.

Indications for Use

Indicated for patients requiring treatment of surgically-created or traumatic osseous defects in the extremities and pelvis, where the void or gap is not intrinsic to bony structure stability.

Regulatory Classification

Identification

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

Submission Summary (Full Text)

{0}------------------------------------------------

Sygnal™ DBM 510(k) Premarket Notification

ﺕ ﺍﻟﺘﻲ

# VII. 510(k) SUMMARY OF SAFETY & EFFECTIVENESS

PROPRIETARY NAME: Sygnal™ DBM COMMON NAME: Bone Void Filler Containing Human Demineralized Bone Matrix (DBM) REGULATORY CLASS: Class II CLASSIFICATION IDENTIFICATION: 21 C.F.R. §888.3045 Resorbable calcium salt bone void filler device PRODUCT CODE: MBP, MOV PANEL CODE: 87-Orthopedic Devices SPONSOR: Musculoskeletal Transplant Foundation 125 May Street Edison, NJ 08837 732-661-0202 723-661-2189 fax

#### INDICATIONS FOR USE:

Sygnal DBM is a bone void filler for voids or gaps that are not intrinsic to the stability of the bony structure. Sygnal DBM can be used to fill bone voids in the extremities and pelvis. It is indicated for use in the treatment of surgically-created osseous defects or osseous defects created from traumatic injury.

Sygnal DBM is for single patient use only.

### DEVICE DESCRIPTION:

Sygnal DBM is completely resorbable and is composed of donated cortical bone. The bone granules are mixed with sodium hyaluronate (Hy) and carboxymethylcellulose (CMC). Sygnal DBM is available in sizes of 0.5 cc, 1.0 cc, 2.5 cc, 5.0 cc, and 10.0 cc.

{1}------------------------------------------------

## SAFETY AND EFFECTIVENESS INFORMATION:

Biocompatibility of Sygnal DBM components has been established through their long history of safe and effective clinical use, further supported by laboratory testing conducted per ISO 10993. Sygnal DBM is single-donor processed using aseptic techniques and is tested for sterility per current USP <71>.

### OSTEOINDUCTIVE POTENTIAL:

Sygnal DBM is osteoconductive, and has been shown to have osteoinductivity potential in an athymic mouse model. Every lot of final product is assayed in vivo for its osteoinductive potential. Standard testing performed in an athymic mouse model must prove positive for lot release. Osteoinduction assay results in the athymic mouse model should not be interpreted to predict clinical performance in human subjects.

## VIRAL CLEARANCE AND INACTIVATION:

The method for processing the demineralized bone matrix contained in Sygnal DBM was evaluated for its viral inactivation potential. A panel of model potential human viruses representing various virus types, sizes, shapes and genomes were evaluated. The DBM processing methods were determined to provide significant viral inactivation potential for a wide range of potential viruses.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes forming its wing. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.

FEB 28 2008

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Musculoskeletal Transplant Foundation % Ms. Nancy Bennewitz Regulatory Affairs Submission Specialist 123 May Street Suite 300 Edison, NJ 08837

Re: K073329

> Trade/Device Name: Sygnal™ DBM Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MBP, MQV Dated: February 20, 2008 Received: February 21, 2008

Dear Ms. Bennewitz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 - Ms. Nancy Bennewitz

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at [phone]. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at [phone]. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number [phone] or [phone] or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely vours.

Mark M. Mulhausen

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

# V. INDICATIONS FOR USE

510(k) Number (if known): not known

Device Name: Sygnal™ DBM

Indications for Use:

Sygnal DBM is a bone void filler for voids or gaps that are not intrinsic to the stability of the bony structure. Sygnal DBM can be used to fill bone voids in the extremities and pelvis. It is indicated for use in the treatment of surgically-created osseous defects or osseous defects created from traumatic injury.

Sygnal DBM is for single patient use only.

OR

Prescription Use X (Per 21 CFR 801 Subpart D) Over-The-Counter Use (Per 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Mark M. Wilkerson

(Division Sign-Off) Division of General, Restorative, and Neurological Devices

510(k) Number

73329